Clinical trials: 2019-nCoV
2019 Novel Coronavirus Infection, COVID-19 Virus Infection
Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19
This trial will study the use of USB002 given as an intravenous infusion in patients with respiratory distress due to infection with COVID-19.
- Conditions
- 2019 Novel Coronavirus Infection, COVID-19 Virus Infection, SARS Coronavirus 2 Infection, SARS-CoV-2 Infection
- Trial name
- NCT04778059
- Testing
- USB002
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- US Biotest, Inc.
COVID-19, 2019 Novel Coronavirus Infection
Evaluating Clinical Parameters of COVID-19 in Pregnancy
Coronavirus infection, also known as COVID-19, has become a global pandemic with over 3 million cases and 250,000 deaths worldwide.
- Conditions
- COVID-19, 2019 Novel Coronavirus Infection, COVID-19 Infection
- Trial name
- COpregVID (NCT04470583)
- Where
- 2 sites in United Kingdom
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
COVID-19, SARS-CoV-2
Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise
The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.
- Trial name
- NCT04472494
- Testing
- Abatacept
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 61 people
- Sponsor
- Bristol-Myers Squibb
COVID
Egyptian Initial Experience About 2019 Novel Corona Virus: Study of 48 Patients in Alexandria-Egypt Using Chest CT
Background: Corona virus disease 2019 (COVID-19) is a highly infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04382469
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Alexandria University
SARS-CoV-2
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in participants aged 6 months to <6 years, when…
- Trial name
- NCT05436834
- Testing
- mRNA-1273.214, mRNA-1273.815
- Where
- 74 sites in United States, Argentina and 5 more
- Volunteers
- 1,807 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Cutaneous Manifestations, Skin Manifestations
Cutaneous Manifestations of Coronavirus Disease 2019(COVID-19).
An outbreak of Corona virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) occurred in Wuhan city, Hubei province, China in December 2019.
- Conditions
- Cutaneous Manifestations, Skin Manifestations, COVID-19, COVID-19 Pneumonia
- Trial name
- NCT05094687
- Where
- Pakistan
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- Jinnah Postgraduate Medical Centre
Coronavirus Disease 2019 (COVID-19) Pneumonia
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19
The primary objective of this study is to assess whether the use of lenzilumab in addition to current standard of care can alleviate the immune-mediated cytokine release syndrome (CRS) and improve ventilator-free survival in…
- Trial name
- NCT04351152
- Testing
- Lenzilumab, Standard of Care
- Where
- 29 sites in United States, Brazil
- Volunteers
- 520 people
- Sponsor
- Humanigen, Inc.
Coronavirus Disease 2019(COVID-19)
Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics of SCTA01(anti-SARS-CoV-2 monoclonal antibody) in Healthy Chinese Subjects.
- Trial name
- NCT04483375
- Testing
- SCTA01
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Covid19
Study to Evaluate Efficacy and Safety of "VIRACIDE" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)
This is a double blind randomized placebo controlled study will be conducted on 124 subjects, 50 years and older with mild or asymptomatic COVID-19.
- Trial name
- NCT04596085
- Testing
- Investigational Product - ViraCide
- Where
- 2 sites in India
- Volunteers
- 118 people
- Sponsor
- The Herb, Inc
SARS-CoV-2 Infection
A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19
The purpose of this post marketing observational study is to learn about the safety and effects of the commercial medicine (called PAXLOVID) for the treatment of COVID-19.
- Trial name
- NCT05263908
- Testing
- nirmatrelvir / ritonavir
- Where
- Japan
- Volunteers
- 3,346 people
- Sponsor
- Pfizer
COVID 19, ARDS
Stellate Ganglion Blockade in Corona Virus 2019 (COVID-19) Positive Patients
This study will establish the safety and efficacy of using stellate ganglion blocks in patients with acute respiratory distress syndrome (ARDS) due to COVID-19 disease.
- Trial name
- NCT04445337
- Testing
- Stellate Ganglion Block
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Nebraska
COVID-19
Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients
The purpose of this research study is to find out if CCP is safe and to determine the safest and most effective level of anti-viral antibody when given to people admitted to the hospital with confirmed COVID-19 infection.
- Trial name
- UNC CCP RCT (NCT04524507)
- Testing
- High-titer Convalescent COVID-19 Plasma (CCP1), Standard-titer Convalescent COVID-19 plasma (CCP2)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of North Carolina, Chapel Hill
2019-nCoV
Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection
Base on Arbidol antiviral therapy,the investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of ASC09 /ritonavir and lopinavir/ritonavir in patients with 2019-nCoV pneumonia.
- Trial name
- NCT04261907
- Testing
- ASC09/ritonavir group, lopinavir/ritonavir group
- Where
- China
- Volunteers
- 6 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Coronavirus
Convalescent Plasma to Limit Coronavirus Associated Complications
Researchers are trying to assess the treatment potential and safety of anti-SARS-CoV-2 convalescent plasma in patients with acute respiratory symptoms with confirmed COVID-19.
- Trial name
- NCT04325672
- Testing
- Convalescent Plasma
- Sponsor
- Mayo Clinic
Healthy, Chronic Stable Illness
COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers
The primary objective of the study is to assess the safety and tolerability of co-formulated subcutaneous (SC) and intravenous (IV) casirivimab+imdevimab The secondary objectives of the study are to: Explore variability in the…
- Trial name
- NCT05181683
- Testing
- Casirivimab+Imdevimab
- Where
- 2 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
COVID-19
Study of Efficacy of Different Treatment Regimens of Olokizumab
The primary objective of the study is to evaluate the efficacy and safety of Artlegia (INN: olokizumab) new dosing regimen in patients with moderate coronavirus infection (COVID-19) with signs of hyperinflammation.
- Trial name
- RESET (NCT05187793)
- Testing
- Olokizumab, Standard therapy
- Where
- 5 sites in Russia
- Volunteers
- 198 people
- Sponsor
- R-Pharm
Mental Disorder
Mental Health and Its Correlates Among Chinese Adolescents Exposed to the Novel Coronavirus Disease 2019
Background: Direct exposure to public health emergencies is associated with increased mental disorders. It is less clear about the prevalence of common mental disorders and its correlates in Chinese adolescents after experiencing…
- Trial name
- NCT04299711
- Testing
- Exposed to the novel coronavirus disease 2019
- Volunteers
- 3,428 people
- Sponsor
- University of Macau
COVID-19
Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19
Study D822FC00005 will investigate the Phamacokinetics, Safety and tolerability of Acalabrutinib suspension when delivered via a nasogastric tube and co-administered with a Proton Pump Inhibitor, in the treatment of COVID-19.
- Trial name
- NCT04497948
- Testing
- Acalabrutinib
- Where
- 4 sites in Brazil
- Volunteers
- 9 people
- Sponsor
- Acerta Pharma BV
COVID-19
VA CoronavirUs Research and Efficacy Studies-1
The purpose of this study is to determine if treatment with convalescent plasma improves the clinical outcomes of Veterans who are hospitalized and require supplemental oxygen due to COVID-19.
- Trial name
- VACURES-1 (NCT04539275)
- Testing
- Convalescent Plasma
- Where
- 24 sites in United States, Puerto Rico
- Volunteers
- 75 people
- Sponsor
- VA Office of Research and Development
COVID-19, SARS-CoV-2
Monitoring Serologic Response to Severe Acute Respiratory Syndrome-2 (SARS-COV-2)/COVID-19 in Children
Individuals susceptible to SARS-CoV-2 and the illness it causes (COVID-19) are comprised of heterogeneous populations with a large risk spectrum for more severe disease.
- Conditions
- COVID-19, SARS-CoV-2, Inflammatory Bowel Diseases
- Trial name
- RECONN (NCT04838834)
- Where
- United States
- Volunteers
- 472 people
- Sponsor
- Connecticut Children's Medical Center